GlioCART GmbH Verified listing Verified listing

  • Swiss Biotech Association
    Member

GlioCART is a University of Basel spin-off focused on translating a dual-action CAR-T therapy for glioblastoma into clinical application by combining tumor targeting with immune microenvironment reprogramming. Our mission is to achieve durable clinical benefit for patients with glioblastoma.

Location

Facts & figures

  • Type of organization
    Private company
  • Year of foundation
    2025
  • Number of employees in Switzerland
    1-9

You may also be interested in